- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02319967
Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes (CHICAGO)
Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes (CHICAGO Plan)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Chicago, Illinois, United States, 60612
- Cook County Health & Hospitals System
-
Chicago, Illinois, United States, 60608
- Sinai Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria (all of the following):
- Child is 5-11 years of age (a population in whom a diagnosis of asthma is generally reliable, and in whom exacerbations are common);
- Child is presenting to the ED, urgent care center, or observation unit at a participating clinical center (Anne and Robert H. Lurie Children's Hospital of Chicago, Sinai Health System's Mount Sinai Hospital, John H. Stroger Jr. Hospital of Cook County Health & Hospitals System, Rush University Medical Center, University of Chicago Medicine Comer Children's Hospital, and the University of Illinois Hospital & Health Sciences System);
- Child is treated with at least 1 dose of an inhaled or nebulized short-acting bronchodilator (quick-relief medication);
- Child received systemic corticosteroids in the ED OR the caregiver reported at least 1 additional acute care visit for asthma in the previous 6 months (defined as an asthma-related ED visit or urgent care visit, or course of systemic corticosteroids);
- Child and caregiver approached at least 1 hour after receipt of the first dose of quick-relief medication or systemic corticosteroids, whichever occurred first;
- Diagnosis of asthma exacerbation by treating clinician;
- Treating ED clinician indicates the child is likely to be discharged to home; and
- Caregiver reports that English or Spanish is the preferred language at home.
Exclusion criteria (none of the following):
- Caregiver declines to provide informed consent, or the child declines to provide assent;
- Child is admitted to an intensive care unit or transferred to another healthcare facility;
- Child or another member of the child's primary household is a current or previous participant in the CHICAGO Plan;
- Child is enrolled in another study involving a health-related intervention;
- A CHW is already visiting the home as part of another program;
- Child does not reside in Chicago.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Enhanced usual care
Inhaler technique education and distribution of spacers to all participants.
|
|
Experimental: ED-only
Inhaler technique education and distribution of spacers to all participants.
Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
|
Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
|
Experimental: ED-plus-home
Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator. Home visits by a community health worker (CHW). |
Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PROMIS Asthma Impact Scale (v1.0, SF8a)
Time Frame: Baseline and 6 months after index ED discharge
|
Raw scores (0-32) were converted to T-scores to measure change from index visit to 6-month primary endpoint. Low scores indicate better asthma; high scores indicate worse asthma. PROMIS Asthma Impact Scale, Pediatric: Min possible T-score: 31.5; Max possible T-score: 76.2 Possible range for change in T-score is [-44.7 to 44.7] PROMIS Asthma Impact Scale, Parent proxy: Min possible T-score: 32; Max possible T-score: 80 Possible range for change in T-score is [-48 to 48] The reported value represents a change in T-score from baseline to 6 months after index ED discharge. A negative change in score indicates improvement in asthma. A positive change in score indicates worsening of asthma. A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
PROMIS Satisfaction With Participation in Social Roles (v1.0, SF4a)
Time Frame: Baseline and 6 months after index ED discharge
|
Raw scores (4-20) were converted to T-scores to measure change from index visit to 6-month primary endpoint. Low scores indicate less satisfaction among caregivers; high scores indicate more satisfaction among caregivers. PROMIS Satisfaction With Participation in Social Roles: Min possible T-score: 29.0; Max possible T-score: 64.1 Possible range for change in T-score is [-35.1 to 35.1] The reported value represents a change in T-score from baseline to 6 months after index ED discharge. A negative change in score indicates less satisfaction among caregivers. A positive change in score indicates a more satisfaction among caregivers. A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Childhood Asthma Control Test (cACT)
Time Frame: Baseline and 6 months after index ED discharge
|
The scores of each item were summed for a total score (0-27) to measure change from index to 6-month primary endpoint. Low scores indicate worse asthma; high scores indicate better asthma. Childhood Asthma Control Test (cACT): Min possible score: 0; Max possible score: 27 Possible range for change in score is [-27 to 27] The reported value represents a change in score from baseline to 6 months after index ED discharge. A negative change in score indicates improvement in asthma. A positive change in score indicates worsening of asthma. A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
PROMIS Anxiety (v1.0, SF4a)
Time Frame: Baseline and 6 months after index ED discharge
|
Raw scores (4-20) were converted to T-scores to measure change from index visit to 6-month primary endpoint. Low scores indicate less anxiety; high scores indicate more anxiety. PROMIS Anxiety: Min possible T-score: 40.3; Max possible T-score: 81.6 Possible range for change in T-score is [-41.3 to 41.3] The reported value represents a change in T-score from baseline to 6 months after index ED discharge. A negative change in score indicates improvement in anxiety. A positive change in score indicates worsening of anxiety. A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
PROMIS Depression (v1.0, SF4a)
Time Frame: Baseline and 6 months after index ED discharge
|
Raw scores (4-20) were converted to T-scores to measure change from index visit to 6-month primary endpoint. Low scores indicate less depression; high scores indicate more depression. PROMIS Depression: Min possible T-score: 41.0; Max possible T-score: 79.4 Possible range for change in T-score is [-38.4 to 38.4] The reported value represents a change in T-score from baseline to 6 months after index ED discharge. A negative change in score indicates improvement in depression. A positive change in score indicates worsening of depression. A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
PROMIS Fatigue (v1.0, SF4a)
Time Frame: Baseline and 6 months after index ED discharge
|
Raw scores (4-20) were converted to T-scores to measure change from index visit to 6-month primary endpoint. Low scores indicate less fatigue; high scores indicate more fatigue. PROMIS Fatigue: Min possible T-score: 33.7; Max possible T-score: 75.8 Possible range for change in T-score is [-42.1 to 42.1] The reported value represents a change in T-score from baseline to 6 months after index ED discharge. A negative change in score indicates improvement in fatigue (i.e., less fatigue). A positive change in score indicates worsening of fatigue (i.e., more fatigue). A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
PROMIS Sleep Disturbance (v1.0, SF4a)
Time Frame: Baseline and 6 months after index ED discharge
|
Raw scores (4-20) were converted to T-scores to measure change from index visit to 6-month primary endpoint. Low scores indicate less sleep disturbance; high scores indicate more sleep disturbance. PROMIS Sleep Disturbance (v1.0, SF4a): Min possible T-score: 32.0; Max possible T-score: 73.3 Possible range for change in T-score is [-41.3 to 41.3] The reported value represents a change in T-score from baseline to 6 months after index ED discharge. A negative change in score indicates improvement in sleep disturbance (i.e., less sleep disturbance). A positive change in score indicates worsening of sleep disturbance (i.e., more sleep disturbance). A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)
Time Frame: Baseline and 6 months after index ED discharge
|
The overall score is the mean score across all 13 items. Each item is scored on a 7-point Likert scale with 1 indicating severe impairment and 7 indicating no impairment. Higher scores indicate better quality of life; lower scores indicate worse quality of life. Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ): Min possible score: 1; Max possible score: 7 Possible range for change in score is [-6 to 6] The reported value represents a change in overall score from baseline to 6 months after index ED discharge. A negative change in score indicates worsening quality of life. A positive change in score indicates improvement in quality of life. A score of 0 indicates no change. |
Baseline and 6 months after index ED discharge
|
Number of Participants With All-cause Emergency Department (ED) or Urgent Care Visits
Time Frame: 6 months post index ED discharge
|
Count of participants (children) with at least one all-cause ED or urgent care visit at 6 months
|
6 months post index ED discharge
|
Number of Participants With All-cause Hospitalizations
Time Frame: 6 months post index ED discharge
|
Count of participants (children) with at least one all-cause hospitalization at 6 months
|
6 months post index ED discharge
|
Self-management Practices After ED Discharge: Number of Participants Who Filled Prescriptions for Systemic Corticosteroids
Time Frame: 7 days post index ED discharge
|
Count of participants who filled a prescription for systemic corticosteroids within 7 days of discharge
|
7 days post index ED discharge
|
Self-management Practices After ED Discharge: Number of Participants Who Filled Prescriptions for Inhaled Corticosteroids or Other Controller
Time Frame: 7 days post index ED discharge
|
Count of participants who filled prescription for inhaled corticosteroids or other controller within 7 days of discharge
|
7 days post index ED discharge
|
Self-management Practices After ED Discharge: Number of Participants Who Attended an Outpatient Appointment With Patient-identified Asthma Provider
Time Frame: 4 weeks post index ED discharge
|
Count of participants who attended follow-up appointment with patient-identifier asthma provider within 4 weeks of discharge
|
4 weeks post index ED discharge
|
Indicator of Guideline-consistent Care Provided on ED Discharge: Number of Participants Who Received Instructions to Use Systemic Corticosteroids
Time Frame: At index ED discharge
|
Count of participants who were provided documented discharge instructions to use systemic corticosteroids
|
At index ED discharge
|
Indicator of Guideline-consistent Care Provided on ED Discharge: Number of Participants Who Received Instructions to Use Inhaled Corticosteroids or Other Controller
Time Frame: At index ED discharge
|
Count of participants who were provided documented discharge instructions to use inhaled corticosteroids or other controller
|
At index ED discharge
|
Indicator of Guideline-consistent Care Provided on ED Discharge: Number of Participants Who Received Instructions to Use Inhaled Rescue Medication
Time Frame: At index ED discharge
|
Count of participants who were provided documented discharge instructions to use an inhaled rescue medication
|
At index ED discharge
|
Indicator of Guideline-consistent Care Provided on ED Discharge: Number of Participants Who Received a Follow-up Appointment Scheduled by ED Staff
Time Frame: At index ED discharge
|
Count of participants who were provided documented discharge instructions for a follow-up appointment scheduled within 4 weeks of discharge
|
At index ED discharge
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jerry A Krishnan, MD, PhD, University of Illinois at Chicago
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-1214
- AS-1307-05420 (Other Grant/Funding Number: PCORI)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on CAPE
-
Nottingham Trent UniversityUniversity of Toronto; University of Manchester; Teesside UniversityNot yet recruiting
-
Ege UniversityCompletedComposite Resins | Matrix Metalloproteinase Inhibitors
-
Sun Yat-sen UniversityRecruitingColon Cancer Stage II | Colon Cancer Stage IIIChina
-
Stanford UniversityNational Cancer Institute (NCI)TerminatedSquamous Cell Carcinoma of the Skin | Recurrent Skin CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Recurrent Breast CancerUnited States
-
Peking University Cancer Hospital & InstituteCompleted
-
Centre Hospitalier René DubosCompletedSchizophrenia SimpleFrance
-
Fox Chase Cancer CenterSirtex MedicalCompletedMetastatic Liver CancerUnited States
-
Peking University Cancer Hospital & InstituteUnknown
-
National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast CancerUnited States